Biotherapeutics startup Hummingbird closes US$25M Series B-plus round led by SK Holdings
Hummingbird Bioscience, a Singapore-operated biotherapeutics company that focusses on the discovery and development of new breakthrough therapies, has closed an extended Series B funding round of US$25 million led by SK Holdings, with participation from existing shareholders including Heritas Capital and SEEDS Capital, the investment arm of Enterprise Singapore.
This brings the total capital raised through financing activities and strategic partnerships to more than US$65 million to date. Hummingbird said it will use the new funds to accelerate the development of new candidates into clinical trials and strengthen the scientific and research and development capabilities.
“Hummingbird is building a strong portfolio of promising new therapies that we believe can deliver very meaningful benefits for patients across a broad spectrum of disease. These new funds give us further resources to develop our early-stage pipeline, and support the clinical development of our lead programs,” said Dr Piers Ingram, Chief Executive Officer, and co-founder, Hummingbird Bioscience.